Sadot Group Inc

This proposal seeks shareholder approval to increase the Company’s authorized common shares dramatically from 2,000,000 to 250,000,000. Management frames the change as a practical governance step to provide capacity for future financings, equity compensation grants, stock dividends or splits, and potential strategic transactions without the expense and delay of convening a special shareholder meeting. From a governance perspective, the board emphasizes flexibility to support growth and to meet Nasdaq listing and registration needs, noting current outstanding shares and reserved shares for existing awards. The potential negative consequences for existing holders are acknowledged: authorization increases enable dilution if shares are issued and can be used defensively in anti-takeover scenarios. The Board recommends a FOR vote, arguing the benefits (capital-raising and transactional flexibility, ability to satisfy equity plan needs) outweigh the dilution risk, especially because there are no present plans to issue the full increase other than known issuances and reserved amounts. Investors should weigh the immediate administrative convenience against the long-term shareholder value risk from dilution and potential use of shares for non-pro rata transactions. The amendment also enables the creation of preferred stock series (10,000,000 preferred shares authorized) which may have governance implications; the board states no present intention to use such measures for anti-takeover purposes. In evaluating the merit of this proposal, sophisticated shareholders should consider management’s near-term capital plan, historic issuance practices, and whether board authorization limits or shareholder pre-approval thresholds are sufficiently protective against opportunistic dilution.

This management-sponsored proposal requests shareholder approval of a new 2025 Equity Incentive Plan that would reserve up to 7,000,000 additional shares for awards to employees, officers, directors, consultants and advisors. Management argues the Plan is central to talent retention and alignment of interests for a growth-stage company, noting existing plans will expire and that equity is a more effective long-term incentive than cash. The Plan authorizes a broad menu of award types (options, SARs, RSUs, restricted stock, bonuses and performance awards), contains standard governance controls (committee administration, limits on grants to any one participant, repricing only with shareholder approval), and includes typical change-in-control and adjustment provisions. From an analytical standpoint, the primary shareholder concerns are dilution and potential excessive concentration of awards among executives; the document discloses guardrails such as per-participant limits (no more than 50% of available shares in a year). The Board’s unanimous recommendation cites the need to maintain market-competitive compensation and avoid difficulty attracting talent if equity grants are unavailable. Investors should assess the Plan’s share reserve relative to current float after the proposed authorized-share increase, vesting and repricing policies, and whether disclosure of executive award opportunities and limits is adequate. The proposal has routine tax-treatment language and claims to preserve potential tax deductibility under Section 162(m) where applicable, though shareholders should note limitations under the tax code. Overall, the Plan is typical for public companies seeking runway for equity-based incentives, and the Board frames approval as necessary to preserve recruiting and retention flexibility.

This proposal asks shareholders to pre-approve potential issuances of common stock to Helena under a September 23, 2025 Purchase Agreement that gives the company the right to sell up to $10 million of common stock to Helena over the commitment period. Management is seeking approval primarily to satisfy Nasdaq Listing Rule 5635 requirements because the aggregate issuances under the facility could trigger Nasdaq thresholds (notably 19.99% or potential change-of-control tests) and because sales could occur at prices tied to VWAP-derived formulas. The Purchase Agreement contains typical mechanics: advances by Helena, pricing at a discount to VWAP, daily value traded caps, an ownership limitation per advance (4.99%), and registration and effectiveness obligations on the Company; the Company agreed to commitment fee shares and potential liquidated damages if filing or effectiveness deadlines are missed. The Board frames the arrangement as a flexible and reliable capital source for working capital without immediate dilution and notes protections such as ownership and registration limits. Analysts should weigh the finance benefits (on-demand access to capital, flexibility) against dilution risks and execution risks (pricing discounts, potential for sizable issuance if facility is drawn) and the potential for investor concentration. Also relevant is the Purchase Agreement’s provisions for make-whole shares and fees, and the Company’s obligations for registration and deadlines, which create contingent liabilities and operational milestones. The Board recommends FOR because the facility enhances liquidity and preserves cash for operations, but shareholders should consider the facility’s terms in conjunction with the proposed authorized share increase and any existing convertible securities that could further dilute holdings.

This proposal asks shareholders to approve the issuance of shares upon conversion of the December 2024 Notes—an aggregate $3.75 million principal amount of convertible notes originally issued in December 2024 and amended multiple times—because, as amended, conversion could result in issuance in excess of Nasdaq thresholds and at formulas tied to low conversion prices (amended to $1.00 or VWAP-based mechanisms). Management’s rationale is pragmatic: allowing conversion preserves the Company’s cash resources for operations and capital needs and reflects negotiated amendments (reduced conversion price, maturity extensions, repayment provisions tied to future offerings). The notes contain investor protections (conversion caps, lock-ups, registration rights, penalties for failure to file or effect registration) and the Company agreed to allocate portions of future offering proceeds to repay these obligations. From an analytical viewpoint, shareholders should examine the economic effect: conversions at low conversion prices are effectively equity financings at potentially dilutive terms; the notes’ MFN clause history and subsequent waivers/amendments suggest complex negotiated dynamics and potential preferential terms for certain investors. The Board emphasizes that approval satisfies Nasdaq’s rule 5635 and avoids forced cash repayments that could stress liquidity. Investors should weigh the dilution risk, the Company’s obligations to register shares, and whether the amended terms (conversion price, caps, lock-ups) appropriately balance creditor-investor rights with shareholder interests. The Board recommends FOR on those practical and liquidity-preserving grounds.

This proposal requests shareholder approval to permit the conversion of the October 2024 Note (original principal $1.375 million, purchased at discount) into common stock under amended terms that lowered or altered the conversion price and extended maturity dates, subject to Nasdaq approval requirements because conversions could exceed 19.99% thresholds or otherwise trigger Nasdaq 5635. Management argues conversion is preferable to cash repayment, conserving company cash and reflecting negotiated amendments including conversion pricing mechanics tied to VWAP and allocation of future offering proceeds toward repayment obligations. Analysts should note the conversion mechanics (originally $1.00 conversion price, later 97% of lowest closing VWAP over three trading days prior to conversion per amendment) and associated lock-ups and percentages of net proceeds required to repay outstanding balances; these terms affect dilution risk and the timeline for potential conversion. The Board recommends FOR on the grounds that conversion lowers cash outflows and resolves debt obligations while providing for lock-ups and certain investor concessions; however, shareholders should consider the dilution impact, the relation to other note conversions (e.g., December 2024 notes), and whether aggregated conversions could materially change ownership. The proposal is largely administrative and compliance-focused—seeking the shareholder approval Nasdaq requires—while the substantive negotiation over conversion economics has already occurred in amendments and waivers.

This proposal seeks shareholder approval to issue 793,000 shares to Aggia pursuant to a November 20, 2025 Settlement Agreement that terminated prior services agreements and related obligations in exchange for an aggregate 1,050,000 settlement shares (257,000 already issued, 793,000 subject to approval) and $75,000 cash. Management frames the settlement as a pragmatic resolution that cancels outstanding promissory notes and governance rights (including board nomination rights) and eliminates ongoing obligations, enabling the Company to move forward without continued contingent liabilities or service obligations. Because the Subsequent Shares would bring the total issued under the settlement above Nasdaq thresholds, shareholder approval is required under Nasdaq Listing Rule 5635(d); the Company commits not to issue the Subsequent Shares absent shareholder approval. From a shareholder-analytic standpoint, the deal converts accrued obligations (often paid in securities to conserve cash) into equity that dilutes existing holders; however, it extinguishes potentially uncertain future claims, board nomination rights, and other encumbrances that could be more costly if litigated or left unresolved. The Board recommends FOR on the basis that the settlement removes governance overhang and ongoing cash drain risks and is in the Company’s and shareholders’ best interests. Investors should evaluate the trade-off between one-time dilution and the removal of strategic and legal risk, including the allocation and pro rata distribution of shares to designated assignees and the timeline for required approvals.